Last week, the US drugmaker and its German partner BioNTech, in a study, showed that their mRNA Covid vaccine is safe, well tolerated and produces robust neutralising antibody responses in children aged 5 to 11 years.
The antibody responses in the participants given 10 microgram doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunised with 30 microgram doses.
Protection from mRNA vaccine against Covid-19 can last only for about six months, or a little more, claimed US drug makers Pfizer and Moderna.
Countries, including the US, UK, Canada and France, have already rolled out vaccines for people aged 12 years old and above.
The team evaluated the SARS-CoV-2 spike immunoglobulin (Ig) G antibody levels after 1 and 2 BNT162b2 doses in previously infected individuals compared with those without previous infection.
In August, Pfizer plans to ask the Food and Drug Administration for emergency authorization of a third dose.
Mixing doses could provide us with even greater flexibility for a booster programme, while also supporting countries who have further to go with their vaccine rollouts, and who may be experiencing supply difficulties.
Researchers at Washington University School of Medicine in St. Louis have found evidence that the immune response to Covid-19 vaccines, namely Pfizer and Moderna, is both strong and potentially long-lasting.
A single dose of either the Pfizer or AstraZeneca Covid-19 vaccine offers around 60 per cent protection against infection from SARS-CoV-2, the virus causing Covid-19, in adults aged 65 years and above, according to a new study published in The Lancet Infectious.
Two doses of Pfizer and AstraZeneca's Covid-19 vaccines are highly effective against hospitalisation from the Delta (B16172) variant, according to a new analysis from Public Health England (PHE).
US pharmaceutical Pfizer's vaccine against Covid-19 can effectively neutralise Beta, Gamma variant of the Coronavirus disease, according to a study.
People fully vaccinated with two doses of the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralising antibodies against the Delta variant (B16172) when compared to the original strain, according to new laboratory data that supports Pfizer's plans to deliver booster shots in Autumn.
New Delhi: The Serum Institute of India (SII) on Saturday broke its silence over the pricing of its Covid-19 vaccine ‘Covishield’ and said that it is the most affordable vaccine…
Washington: Patients without COVID-19 symptoms are far less likely to test positive, and unknowingly spread COVID-19 ten days after receiving a second dose of a messenger RNA vaccine, compared to those who have not been vaccinated, a study says. Researchers from Mayo Clinic in the US noted that several vaccines are now clinically available under […]
Bhubaneswar: The whole of the country, including Odisha, is all geared up to witness the V- Day (Vaccine day), and the time is quite right to know all minute details about the vaccinology. In fact, Vaccinology is the study that tells how a vaccine works and what will be its relationship with the host (means […]
New Delhi: The Union Health Ministry on Friday said that the Covid-19 vaccine will be safe and effective but could show minor side effects like fever and pain at the injection site, adding that taking its shot will be voluntary. The comment comes at a time when questions are being raised at the safety and […]
New York: Taking a big jump towards delivering an effective vaccine to fight the pandemic, US-based pharmaceutical major Pfizer and German biotech firm BioNTech on Monday said that their vaccine candidate was found to be more than 90 per cent effective in preventing Covid-19 in first interim analysis of data from late stage Phase-3 trial. […]